Market Closed -
Other stock markets
|
After market 16:59:46 | |||
9.76 EUR | -4.97% | 9.785 | +0.26% |
05-14 | Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment | MT |
05-14 | Centogene N.V and Evotec SE Discovers Promising New Molecule to Treat Gaucher Disease | CI |
Sales 2024 * | 874M 948M 74.92B | Sales 2025 * | 1.04B 1.12B 88.92B | Capitalization | 1.82B 1.97B 156B |
---|---|---|---|---|---|
Net income 2024 * | -29M -31.44M -2.49B | Net income 2025 * | 34M 36.86M 2.91B | EV / Sales 2024 * | 2.39 x |
Net Debt 2024 * | 269M 292M 23.06B | Net Debt 2025 * | 235M 255M 20.14B | EV / Sales 2025 * | 1.98 x |
P/E ratio 2024 * |
-61.9
x | P/E ratio 2025 * |
32.6
x | Employees | 5,061 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.64% |
Latest transcript on Evotec SE
1 day | -2.00% | ||
1 week | +5.46% | ||
Current month | +3.08% | ||
1 month | -24.00% | ||
3 months | -26.98% | ||
6 months | -46.28% | ||
Current year | -52.82% |
Managers | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 18/06/19 |
Laetitia Rouxel
DFI | Director of Finance/CFO | 51 | 06/02/23 |
Craig Johnstone
COO | Chief Operating Officer | 54 | 30/04/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 18/06/19 |
Roland Sackers
BRD | Director/Board Member | 56 | 18/06/19 |
Chairman | 63 | 16/06/14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.68% | 17 M€ | -.--% | - | |
2.59% | 202 M€ | -.--% | ||
0.21% | 79 M€ | -.--% | ||
0.15% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
17/05/24 | 9.76 | -4.97% | 1 830 327 |
16/05/24 | 10.27 | -2.00% | 1,238,389 |
15/05/24 | 10.48 | +2.04% | 1,405,214 |
14/05/24 | 10.27 | +3.01% | 1,830,577 |
13/05/24 | 9.97 | +4.73% | 2,080,093 |
Delayed Quote Xetra, May 17, 2024 at 12:20 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-52.82% | 1.98B | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.28% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- EVT Stock